THOMAS MONATH to Genetic Vectors
This is a "connection" page, showing publications THOMAS MONATH has written about Genetic Vectors.
Connection Strength
1.284
-
Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine. 2015 Jan 01; 33(1):62-72.
Score: 0.356
-
Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus. Viruses. 2013 Dec 09; 5(12):3048-70.
Score: 0.335
-
Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol. 2000 Feb; 74(4):1742-51.
Score: 0.128
-
Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology. 1999 May 10; 257(2):363-72.
Score: 0.122
-
Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains. Vaccine. 2016 12 12; 34(51):6610-6616.
Score: 0.100
-
Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010 Jan 08; 28(3):632-49.
Score: 0.063
-
Viral vectors for malaria vaccine development. Vaccine. 2007 Mar 30; 25(14):2567-74.
Score: 0.050
-
Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis. 2003 Oct 15; 188(8):1213-30.
Score: 0.041
-
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of viral vector vaccines. Vaccine. 2020 11 17; 38(49):7708-7715.
Score: 0.033
-
Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting. Vaccine. 1997 Oct; 15(14):1494-502.
Score: 0.027
-
Safety and immunogenicity of the rVSV?G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Lancet Infect Dis. 2017 08; 17(8):854-866.
Score: 0.027